NEWS: Creso Pharma $COPHF and Red Light Holland Merge to Introduce The HighBrid LabTM, a Leading Global Psychedelics x Cannabis Company, Specializing in Recreational Products, Applied Science, Technology and Innovation
Red Light Holland hosted a Live Stream on www.youtube.com/redlightholland
Creso Pharma and Red Light Holland have entered into a definitive agreement to merge their businesses and create The HighBrid Lab
The HighBrid Lab is expected to have an implied pro forma equity value of $371 million (C$347 million) based on the closing price of the shares of Creso Pharma and Red Light Holland on 15 June 2021
* Mr. Bruce Linton, leading cannabis and psychedelics entrepreneur, expected to join
as Non-Executive Chairman of The HighBrid Lab’s board of directors
* Combined Company is expected to have a cash balance of approximately A$48
million, providing considerable financial flexibility to progress its growth strategy
* The Combined Global Company will trade on the Canadian Securities Exchange
(“CSE”) under the ticker symbol TRIP
* The HighBrid Lab will focus on several key growth areas:
* Expanding market and brand leadership in recreational psilocybin, supported by
education, telecounseling and technology as new markets open
* Applied science and innovation supporting long-term opportunities in
psychedelics with both naturally occurring and pharmaceutical grade drug
discovery aiming for advanced and approved product offerings through controlled
lab environments via the pending acquisitions of Halucenex and Mera Life
Sciences
* Once merged, The Highbrid Lab is able to immediately commence selling its
Animal and Human CBD products within the USA which is expected to add
considerable revenue
*Scaling recreational cannabis offering in North America by focusing on increasing market share in Canada and taking advantage of the Combined Company’s CSE listing to progress the introduction of products into the US, as well as leveraging ABN: 89 609 406 911
Red Light Holland hosted a Live Stream on www.youtube.com/redlightholland
Creso Pharma and Red Light Holland have entered into a definitive agreement to merge their businesses and create The HighBrid Lab
The HighBrid Lab is expected to have an implied pro forma equity value of $371 million (C$347 million) based on the closing price of the shares of Creso Pharma and Red Light Holland on 15 June 2021
* Mr. Bruce Linton, leading cannabis and psychedelics entrepreneur, expected to join
as Non-Executive Chairman of The HighBrid Lab’s board of directors
* Combined Company is expected to have a cash balance of approximately A$48
million, providing considerable financial flexibility to progress its growth strategy
* The Combined Global Company will trade on the Canadian Securities Exchange
(“CSE”) under the ticker symbol TRIP
* The HighBrid Lab will focus on several key growth areas:
* Expanding market and brand leadership in recreational psilocybin, supported by
education, telecounseling and technology as new markets open
* Applied science and innovation supporting long-term opportunities in
psychedelics with both naturally occurring and pharmaceutical grade drug
discovery aiming for advanced and approved product offerings through controlled
lab environments via the pending acquisitions of Halucenex and Mera Life
Sciences
* Once merged, The Highbrid Lab is able to immediately commence selling its
Animal and Human CBD products within the USA which is expected to add
considerable revenue
*Scaling recreational cannabis offering in North America by focusing on increasing market share in Canada and taking advantage of the Combined Company’s CSE listing to progress the introduction of products into the US, as well as leveraging ABN: 89 609 406 911
